Different doses of ADVATE for immune tolerance in boys with hemophilia A and inhibitors
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests how different doses and schedules of the factor VIII medicine ADVATE can train the immune system to accept factor VIII again in boys with hemophilia A who have developed inhibitors. The goal is to find a better way to help their bodies stop blocking the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe hemophilia A (factor VIII level less than 2%)
- You have tested positive for factor VIII inhibitors
- You have never had an allergic reaction to factor VIII concentrates, like ADVATE
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
This study tests a new approach to immune tolerance induction (ITI) in young people with severe hemophilia A who have a high-titer inhibitor. It uses a specific clotting factor combined with emicizumab to try to retrain the immune system so that standard treatments work again.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This study tests a new treatment called elranatamab to help your body get rid of the inhibitor that blocks factor VIII replacement therapy. The goal is to make standard hemophilia treatment work better for you.
This early-phase study tests an FVIII gene therapy to help your body make more of the missing clotting factor in hemophilia A. It’s aimed at adults with severe low FVIII levels who have already used FVIII replacement products for a long time and have not developed an immune blocker (an inhibitor).
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
Hear when a new Hemophilia A With Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.